Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Grows By 355.3%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 22,704 shares, a growth of 355.3% from the March 31st total of 4,987 shares. Based on an average daily volume of 21,902 shares, the short-interest ratio is currently 1.0 days. Approximately 1.3% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on BOLT shares. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a report on Friday, March 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and an average price target of $34.00.

Institutional Trading of Bolt Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after acquiring an additional 26,400 shares during the period. Susquehanna International Group LLP bought a new stake in shares of Bolt Biotherapeutics during the 3rd quarter valued at $89,000. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics during the 3rd quarter valued at $85,000. Squarepoint Ops LLC boosted its holdings in shares of Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares in the last quarter. Finally, T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $208,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Stock Performance

Shares of BOLT stock opened at $4.83 on Monday. The stock has a fifty day moving average of $4.61 and a 200 day moving average of $5.21. Bolt Biotherapeutics has a 52 week low of $3.91 and a 52 week high of $9.25. The firm has a market capitalization of $9.27 million, a price-to-earnings ratio of -0.27 and a beta of 0.86. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.76.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($3.84) EPS for the quarter, topping analysts’ consensus estimates of ($4.27) by $0.43. Bolt Biotherapeutics had a negative return on equity of 92.54% and a negative net margin of 433.74%.The company had revenue of $2.50 million during the quarter, compared to analyst estimates of $0.67 million. As a group, research analysts expect that Bolt Biotherapeutics will post -11.26 earnings per share for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.